UR-2922, with the CAS number 220386-56-1, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in pharmacology. It is characterized by its unique molecular structure, which contributes to its biological activity. UR-2922 is known to interact with specific receptors in the body, potentially influencing various physiological processes. Its solubility, stability, and reactivity are important factors that determine its efficacy and safety profile in therapeutic contexts. Additionally, UR-2922 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which are critical for understanding its behavior in biological systems. Research into UR-2922 is ongoing, focusing on its mechanisms of action, potential therapeutic uses, and any associated side effects. As with many compounds in drug development, thorough investigation and characterization are essential to establish its viability as a therapeutic agent.

UR-2922 is a new generation oral platelet GPIIb/IIIa antagonist. UR-2922 is the active form of the prodrug UR-3216. UR-2922 possessed a high affinity for the human platelet receptor (K(d) <1 nM) with a slow dissociation rate (k(off)= 90 min) in vitro. UR-2922 induced no ligand-induced binding sites (LIBS) expression or prothrombotic activity in human platelets, distinctly different from orbofiban and other small molecule antagonists.

UR-2922

220386-56-1: UR-2922, with the CAS number 220386-56-1, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in pharmacology. It is characterized by its unique molecular structure, which contributes to its biological activity. UR-2922 is known to interact with specific receptors in the body, potentially influencing various physiological processes. Its solubility, stability, and reactivity are important factors that determine its efficacy and safety profile in therapeutic contexts. Additionally, UR-2922 may exhibit specific pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, which are critical for understanding its behavior in biological systems. Research into UR-2922 is ongoing, focusing on its mechanisms of action, potential therapeutic uses, and any associated side effects. As with many compounds in drug development, thorough investigation and characterization are essential to establish its viability as a therapeutic agent.

<p>UR-2922: Oral GPIIb/IIIa blocker with &lt;1 nM affinity, slow 90 min k(off), no LIBS or prothrombotic effects.</p>

CAS 220386-56-1

UR-2922

UR-2922

Ref: TM-T29073